BMC BiologyMolecular BiologyPeer-reviewed journal article
Megabase-scale Transgene De-Duplication to Generate a Functional Single-Copy Full-Length Humanized DMD Mouse Model
Yu Chinn Joshua CheyiD, Mark A CorbettiD, Jayshen ArudkumariD, Sandra PiltziD, Paul Quinton ThomasiD, Fatwa AdikusumaiD
Abstract
The development of sequence-specific precision treatments like CRISPR gene-editing therapies for Duchenne Muscular Dystrophy (DMD) requires sequence humanised animal models to enable the direct clinical translation of tested strategies. The current available integrated transgenic mouse model containing the full-length human DMD gene, Tg(DMD)72Thoen/J (hDMDTg), has been found to have two copies of the transgene per locus in a tail-to-tail orientation, which does not accurately simulate the true copy number of the DMD gene. This duplication also complicates the analysis when testing CRISPR therapy editing outcomes, as large genetic alterations and rearrangements can occur between the cut sites on the two transgenes. To address this, we performed long read nanopore sequencing on hDMDTg mice to better understand the structure of the duplicated transgenes. Following that, we performed a megabase-scale deletion of one of the transgenes by CRISPR zygotic microinjection to generate a single-copy, full-length, humanised DMD transgenic mouse model (hDMDTgSc). Functional, molecular, and histological characterisation show that the single remaining human transgene retains its function and rescues the dystrophic phenotype caused by endogenous murine Dmd knockout. Our unique hDMDTgSc mouse model can potentially be used to further generation of DMD disease models, suited for the pre-clinical assessment of sequence-specific therapies.
- Citations
- 7
- FWCI
- 0.95
- Field percentile
- top 28%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Four new Duchenne muscular dystrophy mouse models with clinically relevant exon deletions in the human DMD gene
Maaike van Putten, Margot M. L. Linssen, … Peter Hohenstein·Disease Models & MechanismsPeer-reviewed·Aug 1, 2026
- Generation and characterisation of mouse models of Duchenne Muscular Dystrophy (DMD)
Jayshen Arudkumar, Yu Chinn Joshua Chey, … Fatwa Adikusuma·BMC MethodsPeer-reviewed·Dec 9, 2024
- CRISPR-induced deletion with SaCas9 restores dystrophin expression in dystrophic models in vitro and in vivo.
Benjamin L. Duchêne, Khadija Cherif, … Jacques P. Tremblay·Molecular TherapyPeer-reviewed·Aug 16, 2018
- Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD
Britt Hanson, Sofia Stenler, … Thomas C. Roberts·Molecular Therapy — Nucleic AcidsPeer-reviewed·Oct 23, 2022
- Duchenne Muscular Dystrophy Cell Culture Models Created By CRISPR/Cas9 Gene Editing And Their Application To Drug Screening
Patricia Soblechero‐Martín, E. Albiasu-Arteta, … Virginia Arechavala‐Gomeza·Scientific ReportsPeer-reviewed·Sep 14, 2021
- Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model
J. Poyatos-Garcia, P. Soblechero-Martin, … J. J. Vilchez·bioRxiv·Sep 13, 2023